Home Tags Mylan
The new company will sell popular drugs such as Viagra, Lipitor, and Mylan's EpiPen, and is expected to generate around $20 billion in total sales.
In June, the Food and Drug Administration extended the expiration date on some EpiPens to help with a shortage of the devices.
Congress will grill 7 top pharma executives over the high cost of drugs today. Here’s how they’re set to shift the blame.
Pharma CEOs are likely to blame drug rebates for the high cost of their treatments, echoing an argument the industry has been using frequently.
EpiPens weren’t working. It took 3 years and the FDA stepping in before serious change — with potentially deadly outcomes
Consumer complaints about EpiPens were increasing, but its manufacturer wasn’t properly looking into those complaints, FDA inspectors warned in 2014.
A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside s...
Business Insider is the first to report on the unredacted suit, which alleges frequent, close communications among employees of rival companies about how to increase prices.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
BI PRIME: Morgan Stanley compiled a list of large and liquid companies it thinks will get at least one tender offer over the next 12 months.